Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.

Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds.

Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds.

A process for preparing an acrylamide-based crosslinking monomer including reacting in the presence of a catalyst an isocyanate compound containing at least two isocyanate groups with one of acrylic acid and methacrylic acid.

A process for preparing an acrylamide-based crosslinking monomer including reacting in the presence of a catalyst an isocyanate compound containing at least two isocyanate groups with one of acrylic acid and methacrylic acid.

A process for preparing an acrylamide-based crosslinking monomer including reacting in the presence of a catalyst an isocyanate compound containing at least two isocyanate groups with one of acrylic acid and methacrylic acid.

The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (CO)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group).

##STR00001##

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (CO)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group).

##STR00001##